SEC Form 4 · accession 0001587221-17-000003
Zosano Pharma Corp · ZSAN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Konstantinos Alataris
Officer — President, CEO · Director
Period of report
Mar 20, 2017
Accepted (ET)
Mar 22, 2017 · 5:39 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001587221
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Mar 20, 2017 | M | 127,389 | $1.45 | A | 254,778 | I | By The Alataris Family Trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Series A Warrants (right to buy) | $1.45 | Mar 20, 2017 | M | 127,389 | D | Aug 19, 2016 | Aug 26, 2017 | Common Stock | 127,389 | 0 | I |